Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-Segmental Vitiligo Clear all

Conditions: Non-Segmental Vitiligo
Interventions: ACT-777991, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-segmental Vitiligo
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 34
States / cities: Gilbert, Arizona • Fremont, California • Irvine, California + 24 more

Conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions: Ritlecitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more

Conditions: Active Non-segmental Vitiligo
Interventions: PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 40
States / cities: Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more

Conditions: Vitiligo
Interventions: Metformin Hydrochloride; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Non-Segmental Vitiligo
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Irvine, California • Redwood City, California • Boca Raton, Florida + 16 more

Conditions: Vitiligo
Interventions: Afamelanotide, Narrow-Band UVB Light Treatment; Drug · Procedure
Lead sponsor: Clinuvel Pharmaceuticals Limited; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Detroit, Michigan • New York, New York

Conditions: Non-segmental Vitiligo
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Hoover, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 24 more

Conditions: Non-segmental Vitiligo
Interventions: MK-6194, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Los Angeles, California + 9 more

Conditions: Non-segmental Vitiligo
Interventions: GIA632, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 21 more

Conditions: Non-segmental Vitiligo
Interventions: VYN201 Gel, Vehicle Gel; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: Vitiligo
Interventions: ATI-50002 topical solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Encinitas, California • Los Angeles, California • Worcester, Massachusetts + 2 more

Conditions: Non-segmental Vitiligo
Interventions: Roflumilast topical 0.3% foam; Drug
Lead sponsor: Derm Texas, PLLC; Network
Eligibility: 2 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Vitiligo
Interventions: Ruxolitinib 1.5% cream, NB-UVB phototherapy; Drug · Device
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Fountain Valley, California • Sacramento, California • Sunnyvale, California + 8 more

Conditions: Vitiligo
Interventions: ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment; Drug · Device
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 5
States / cities: San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more

Conditions: Non-segmental Vitiligo
Interventions: EI-001, Placebo; Biological · Other
Lead sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Huntington Beach, California • Hollywood, Florida • Worcester, Massachusetts + 3 more

Conditions: Non-segmental Vitiligo
Interventions: AS012, Placebo; Drug
Lead sponsor: Ache Laboratorios Farmaceuticos S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Bryant, Arkansas • Fremont, California + 16 more

Conditions: Vitiligo
Interventions: Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more

Conditions: Vitiligo, Non-Segmental Vitiligo (NSV)
Interventions: LY4005130, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Fremont, California • Northridge, California + 14 more

Search by objective public record fields.

A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Evaluating the Efficacy and Safety of Metformin in Vitiligo

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo